financetom
Business
financetom
/
Business
/
Form 8.3
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3
Nov 24, 2025 7:26 AM

LONDON--(BUSINESS WIRE)--

 

Ap27

FORM 8.3

IRISH TAKEOVER PANEL

OPENING POSITION DISCLOSURE/DEALING DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER

RULES, 2022 BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1. KEY INFORMATION

(a) Full name of discloser

BALYASNY ASSET MANAGEMENT L.P.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a)

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates

Use a separate form for each offeror/offeree

Avadel Pharmaceuticals plc

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree (Note 1)

 

(e) Date position held/dealing undertaken

For an opening position disclosure, state the latest practicable date prior to the disclosure

21/11/2025

(f) In addition to the company in 1(c) above, is the discloser also making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

 

2. INTERESTS AND SHORT POSITIONS

If there are interests and short positions to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2 for each additional class of relevant security.

Ap28

Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

(Note 2)

Class of relevant security
(Note 3)

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

3,565,609

3.65

54

0.00

(2) Cash-settled derivatives

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

 

 

 

 

Total

3,565,609

3.65

54

0.00

All interests and all short positions should be disclosed.

Details of options including rights to subscribe for new securities and any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8.

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE (Note 4)

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant
security

Purchase/sale

Number of
securities

Price per unit
(Note 5)

%0.01 ordinary shares

Purchase

69,250

USD 22.80

%0.01 ordinary shares

Purchase

8

USD 23.02

%0.01 ordinary shares

Purchase

1

USD 23.02

%0.01 ordinary shares

Purchase

2

USD 23.04

%0.01 ordinary shares

Purchase

4

USD 22.98

%0.01 ordinary shares

Purchase

3

USD 23.03

%0.01 ordinary shares

Purchase

1

USD 23.03

%0.01 ordinary shares

Purchase

1

USD 22.92

%0.01 ordinary shares

Purchase

1

USD 22.93

%0.01 ordinary shares

Purchase

184

USD 23.03

%0.01 ordinary shares

Purchase

1

USD 23.03

%0.01 ordinary shares

Purchase

2

USD 23.03

%0.01 ordinary shares

Purchase

19,721

USD 22.85

%0.01 ordinary shares

Purchase

100

USD 23.02

%0.01 ordinary shares

Purchase

450,349

USD 23.05

%0.01 ordinary shares

Purchase

10,730

USD 22.97

%0.01 ordinary shares

Sale

12

USD 22.91

%0.01 ordinary shares

Sale

2

USD 22.80

%0.01 ordinary shares

Sale

8

USD 22.90

%0.01 ordinary shares

Sale

8

USD 22.92

%0.01 ordinary shares

Sale

125

USD 23.04

%0.01 ordinary shares

Sale

2

USD 22.88

%0.01 ordinary shares

Sale

13

USD 22.80

%0.01 ordinary shares

Sale

4

USD 22.91

%0.01 ordinary shares

Sale

3

USD 22.80

%0.01 ordinary shares

Sale

16

USD 22.93

%0.01 ordinary shares

Sale

10

USD 22.91

%0.01 ordinary shares

Sale

14

USD 22.92

%0.01 ordinary shares

Sale

4

USD 22.94

%0.01 ordinary shares

Sale

25

USD 23.02

%0.01 ordinary shares

Sale

47

USD 23.03

%0.01 ordinary shares

Sale

2

USD 22.82

%0.01 ordinary shares

Sale

11

USD 22.94

%0.01 ordinary shares

Sale

3

USD 22.87

%0.01 ordinary shares

Sale

2

USD 22.93

%0.01 ordinary shares

Sale

4

USD 22.95

%0.01 ordinary shares

Sale

12

USD 22.92

%0.01 ordinary shares

Sale

5

USD 22.93

%0.01 ordinary shares

Sale

6

USD 22.92

%0.01 ordinary shares

Sale

8

USD 22.91

%0.01 ordinary shares

Sale

2

USD 22.92

%0.01 ordinary shares

Sale

14

USD 22.90

%0.01 ordinary shares

Sale

27

USD 22.92

%0.01 ordinary shares

Sale

8

USD 22.91

Ap29

(b) Cash-settled derivative transactions

Class of
relevant
security

Product
description
e.g. CFD

Nature of dealing
e.g. opening/ closing a long/ short position, increasing/ reducing a long/ short position

Number of
reference
securities
(Note 6)

Price
per unit
(Note 5)

 

 

 

 

 

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of
relevant
security

Product
description e.g. call
option

Writing, purchasing, selling, varying
etc.

Number
of
securities
to which
option
relates
(Note 6)

Exercise
price per
unit

Type
e.g.
American,
European
etc.

Expiry
date

Option
money
paid/
received per unit

 

 

 

 

 

 

 

 

(ii) Exercise

Class of
relevant
security

Product
description
e.g. call
option

Exercising/
exercised
against

Number of
securities

Exercise
price per
unit
(Note 5)

 

 

 

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

Class of
relevant
security

Nature of dealing
e.g. subscription,
conversion, exercise

Details

Price per unit (if
applicable)
(Note 5)

 

 

 

 

Ap30

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer.

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

(c) Attachments

Is a Supplemental Form 8 attached?

No

Class of relevant security
(Note 3)

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled

3,565,609

3.65

54

0.00

(2) Cash-settled derivatives

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/ sell

 

 

 

 

Total

3,565,609

3.65

54

0.00

0

Public disclosures under Rule 8.3 of the Rules must be made to a Regulatory Information Service.

Ap31

NOTES ON FORM 8.3

1. See the definition of “connected fund manager” in Rule 2.2 of Part A of the Rules.

2. See the definition of “interest in a relevant security” in Rule 2.5 of Part A of the Rules and see Rule 8.6(a) and (b) of Part B of the Rules.

3. See the definition of “relevant securities” in Rule 2.1 of Part A of the Rules.

4. See the definition of “dealing” in Rule 2.1 of Part A of the Rules.

5. If the economic exposure to changes in the price of securities is limited, for example, by virtue of a stop loss arrangement relating to a spread bet, full details must be given.

6. See Rule 2.5(d) of Part A of the Rules.

7. If details included in a disclosure under Rule 8 are incorrect, they should be corrected as soon as practicable in a subsequent disclosure. Such disclosure should state clearly that it corrects details disclosed previously, identify the disclosure or disclosures being corrected, and provide sufficient detail for the reader to understand the nature of the corrections. In the case of any doubt, the Panel should be consulted.

For full details of disclosure requirements, see Rule 8 of the Rules. If in doubt, consult the Panel.

References in these notes to “the Rules” are to the Irish Takeover Panel Act, 1997, Takeover Rules, 2022.

Source: Balyasny Asset Management LP

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Congo sticking to cobalt export quotas, keen to boost processing
Congo sticking to cobalt export quotas, keen to boost processing
Sep 24, 2025
NEW YORK, Sept 24 (Reuters) - Democratic Republic of Congo will stick to its recently announced quota system for cobalt exports, with revisions only possible in the long term if the government sees them as necessary, the country's mining minister said on Wednesday. The mining minister, Louis Watum Kabamba, told Reuters in an interview on the sidelines of a seminar...
Update: Cidara's Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September; Shares Rise
Update: Cidara's Phase 3 Trial of Influenza Prevention Drug CD388 to Begin in September; Shares Rise
Sep 24, 2025
01:38 PM EDT, 09/24/2025 (MT Newswires) -- (Updates with stock price movement in the headline and the first paragraph.) Cidara Therapeutics ( CDTX ) shares rose more than 22% in recent Wednesday trading after the company said it will start enrolling patients for a phase 3 trial of CD388 by the end of September following its end-of-phase 2 meeting with...
Pelangio Exploration Upsizes Private Placement of Units to $4.5 Million
Pelangio Exploration Upsizes Private Placement of Units to $4.5 Million
Sep 24, 2025
12:59 PM EDT, 09/24/2025 (MT Newswires) -- Pelangio Exploration ( PGXPF ) on Wednesday said it upsized a non-brokered private placement of share units to $4.5 million from $4 million. The units will be priced at $0.18 each and consist of one share and half a two-year warrant to buy a share at $0.31. Proceeds will be used for exploration...
Update: UniQure's Shares Soar After Phase 1/2 Trial in Huntington's Disease Meets Primary Endpoint
Update: UniQure's Shares Soar After Phase 1/2 Trial in Huntington's Disease Meets Primary Endpoint
Sep 24, 2025
01:39 PM EDT, 09/24/2025 (MT Newswires) -- (Updates with stock move in the headline and first paragraph.) UniQure's ( QURE ) shares rose past 234% in recent Wednesday trading after the company said that its phase 1/2 study in Huntington's disease met its primary endpoint, with high-dose AMT-130 showing statistically significant 75% slowing of disease at 36 months as measured...
Copyright 2023-2025 - www.financetom.com All Rights Reserved